Displaying items by tag: oneal comprehensive cancer center

A UAB researcher has received a 2017 Susan G. Komen grant to investigate combination drug therapies for HER2-positive breast cancer.
Cancer is a disease with a thousand faces. Oncologists like Eddy Yang have to recognize which one they’re seeing with each new patient. Yang leads a pioneering new kind of cancer program at UAB: the Molecular Tumor Board.
In two new studies, a UAB oncologist explores questions of choice and cost in metastatic breast cancer.
nycu graphic 2Surgeon at UAB believes in making breast cancer awareness an issue year-round to help save lives through early detection.
This grant will fully support Kendra Royston’s research work within the UAB College of Arts and Sciences’ Department of Biology throughout the spring of 2018.
Researchers use compounds found in a combination plant-based diet to successfully prevent and treat ER-negative breast cancer in mice.
Chad Thomas Hagwood, Edward E. Partridge, Catherine Danielou, Michelle Cardel and Raymond Thompson were bestowed the awards by the NAS for their personal, academic and professional achievements, service to the community, and philanthropy.
A blue-light cystoscopy may detect certain bladder cancer tumors more than the use of standard white-light diagnostic testing.
Hadiyah-Nicole Green, UAB alumna, will be recognized by GE in a Grand Central Station display for research in cancer treatment.

Alina Franke registered to donate her bone marrow in Hamburg, Germany, in 2009. She wound up being the one person in 24 million around the world on the Be The Match registry to be the perfect match that Jimmy Roberson needed.

These new results, led by primary author Warner Huh, M.D., strengthen the promise that vaccination with Gardasil 9 can reduce 90 percent of cervical cancers.

This gene silencing by ubiquitinated histone is vital in normal embryo development, and it goes awry in some cancers.
An art event will be held Aug. 17 to engage the cancer community in the healing power of art.
This potential chemotherapeutic agent to treat glioblastoma — a primary brain tumor with dismal survival rates — is a novel small molecule inhibitor.
UAB is the only institution in Alabama chosen to date to participate in the TAPUR Study to help further understand targeted therapies in patients with advanced cancers.
Page 20 of 34